Intercept Pharmaceuticals Director Lorenzo Tallarigo Unloads 1,839 Shares (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) Director Lorenzo Tallarigo sold 1,839 shares of the company’s stock on the open market in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $67.41, for a total value of $123,966.99. Following the sale, the director now directly owns 1,640 shares of the company’s stock, valued at approximately $110,552. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 281.09% on Thursday, hitting $275.87. The stock had a trading volume of 6,840,347 shares. Intercept Pharmaceuticals has a 52-week low of $30.38 and a 52-week high of $305.00. The stock has a 50-day moving average of $66.99 and a 200-day moving average of $55.33. The company’s market cap is $5.334 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($1.65) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.51) by $1.14. During the same quarter in the prior year, the company posted ($1.86) earnings per share. Analysts expect that Intercept Pharmaceuticals will post $-3.45 EPS for the current fiscal year.
Separately, analysts at BMO Capital Markets raised their price target on shares of Intercept Pharmaceuticals to $270.00 in a research note to investors on Thursday. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $106.80.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.